Soligenix Inc. applies for funding to develop an Ebola vaccine. Ebola vaccine funding application may moderately advance Soligenix pipeline and investor interest.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | 1 | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 8.45 | 7.82 | 7.94 | 9.81 |
| Receivables | 0.20 | — | — | — |
| Inventory | 0.17 | — | — | — |
| Other | — | 0.10 | 0.02 | 0.01 |
| 9.51 | 8.83 | 8.85 | 10.17 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 1.11 | 0.67 | 1.12 | 1.41 |
| ST’ Debt | 2.25 | 1.37 | — | — |
| Other | — | — | — | — |
| 6.15 | 4.85 | 3.70 | 3.67 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’24 | 0.12 | 0.00 | — | — |
0.12
|
| ’23 | 0.26 | 0.21 | 0.13 | 0.24 |
0.84
|
| ’22 | 0.19 | 0.23 | 0.17 | 0.37 |
0.95
|
| ’21 | 0.15 | 0.21 | 0.19 | 0.28 |
0.82
|
| ’20 | 0.92 | 0.51 | 0.61 | 0.32 |
2.36
|
| ’19 | 1.14 | 1.55 | 1.25 | 0.69 |
4.63
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (2.36) | (1.71) | — | — |
—
|
| ’25 | (1.85) | (2.74) | (2.93) | (2.75) |
(10.27)
|
| ’24 | (1.34) | (1.92) | (2.91) | (2.23) |
(8.40)
|
| ’23 | (2.17) | (1.92) | (2.69) | (1.83) |
(8.60)
|
| ’22 | (3.24) | (2.53) | (3.25) | (3.63) |
(12.65)
|
| ’21 | (3.99) | (1.66) | (3.04) | (3.06) |
(11.74)
|
| ’20 | (2.70) | (1.64) | (2.99) | (4.12) |
(11.45)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (2.36) | (1.71) | — | — |
—
|
| ’25 | (1.85) | (2.75) | (2.93) | (2.75) |
(10.27)
|
| ’24 | (1.34) | (1.92) | (2.91) | (2.23) |
(8.40)
|
| ’23 | (2.17) | (1.92) | (2.69) | (1.83) |
(8.60)
|
| ’22 | (3.25) | (2.53) | (3.25) | (3.63) |
(12.66)
|
| ’21 | (3.99) | (1.66) | (3.04) | (3.07) |
(11.75)
|
| ’20 | (2.70) | (1.64) | (2.99) | (4.12) |
(11.46)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.28) | (0.12) | — | — |
—
|
| ’25 | (1.06) | (0.82) | (0.58) | — |
(2.14)
|
| ’24 | (2.88) | (1.31) | (0.78) | (1.14) |
(4.98)
|
| ’23 | (5.76) | (3.52) | (2.56) | (2.56) |
(12.64)
|
| ’22 | (23.99) | (14.39) | (19.19) | (1.30) |
(76.96)
|
| ’21 | (14.39) | (11.99) | (21.59) | (26.39) |
(74.36)
|
| ’20 | (76.76) | (23.99) | (14.39) | (45.58) |
(153.52)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 91.20 | 6.08 | 1.83 | 1.09 | — | — | — |
Low Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 240.00 | 129.60 | 19.20 | 6.23 | — | — | — |
High Price
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 15 | 15 | 16 | 14 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.06 | 0.06 | 0.01 | 0.00 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.95 | 0.84 | 0.12 | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 41.95% | 11.59% | 0.00% | — | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (14.95) | (7.91) | (8.68) | (11.59) | ‡‡‡‡‡ | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1,575.86%) | (942.16%) | (7,266.08%) | 0.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.80) | (6.14) | (8.27) | (11.08) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.07 | 0.02 | 0.01 | 0.00 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | 5.29 | 1.73 | 0.07 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (76.96) | (12.64) | (4.98) | (2.14) | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (70.51) | (17.74) | (5.06) | (1.98) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.07) | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (70.58) | (17.74) | (5.06) | (1.98) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.77) | 5.20 | 2.48 | 1.02 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.18 | 0.49 | 1.66 | 5.19 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 21.78 | 7.86 | 9.06 | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | 0.00 | 2.62 | 1.09 | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 18.38 | 1.68 | (1.93) | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.38) | (0.16) | 0.11 | — | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.65) | (8.60) | (8.40) | (10.27) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.01) | — | — | (0.01) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.66) | (8.60) | (8.40) | (10.27) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.66) | 3.36 | 3.98 | 5.15 | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10.13 | 3.26 | 1.37 | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3.23) | (5.19) | (6.45) | (7.94) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.47) | 2.52 | 4.12 | 5.29 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (67.06%) | (51.01%) | (88.11%) | (121.75%) | ‡‡‡‡‡ | — | — |
ROA
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (334.43%) | (23,801.16%) | (248.98%) | (235.50%) | ‡‡‡‡‡ | — | — |
ROE
|
Soligenix Inc. (SNGX), a microcap biotech targeting rare diseases and biothreats, exemplifies speculative peril with a revenue collapse from $10.4 million in 2016 to just $119,400 in 2024—a 98.9% drop—amid stalled commercialization and trial delays for assets like SGX301. Shares outstanding have ballooned 11,345% through relentless dilution, eroding book value per share by 99.5% and fueling chronic cash burns of over $8 million annually, leaving scant runway despite a modest cash buffer.
While a single analyst’s $10 price target suggests 800% upside, fundamentals paint a grim picture: deepening losses projected to -76 cents EPS by 2027, negative margins, and a history of hype-driven spikes followed by 99%+ crashes on milestone misses. A minor $20,000 insider buy by the CEO offers faint conviction, but operational entropy and binary biotech risks dominate.
Projections hint at tepid revenue recovery to $500,000 by 2025 alongside widening losses and further share bloat, banking on catalysts like Phase 3 data or biothreat contracts—yet dilution’s toll and solvency red flags scream caution. Is this a contrarian lottery ticket or another biotech graveyard resident? Dive into the full analysis for the unvarnished dissection.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.